Elderly – Trelegy Ellipta may be used in the elderly.
The effect of fluticasone furoate/umeclidinium/vilanterol has not been evaluated in subjects with renal impairment.
The effects of haemodialysis have not been studied.
Hepatic impairment – Caution is advised in moderate to severe hepatic impairment, but no specific dose adjustment based on hepatic function is recommended. There was no significant increase in systemic exposure to vilanterol.
Precautions for storage – The inhaler should be kept inside the sealed tray to protect from moisture and only remove immediately before first use. The date that the inhaler should be discarded should be written on the label and carton in the space provided. The date should be added as soon as the inhaler has been removed from the tray. Shelf-life after opening the tray: 6 weeks.
Patients should not stop therapy with Trelegy Ellipta without medical supervision since symptoms may recur after discontinuation.